Cargando…

Editorial: Advances on targeted nanomedicines for atherosclerosis

The importance of nanomedicines for atherosclerosis. [Image: see text]

Detalles Bibliográficos
Autores principales:	Han, Qinggong, He, Hongliang, Zhang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615546/ https://www.ncbi.nlm.nih.gov/pubmed/36313335 http://dx.doi.org/10.3389/fphar.2022.1053938

Ejemplares similares

Editorial: Advances and Challenges in Nanomedicine
por: Hua, Susan, et al.
Publicado: (2018)

Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications
por: Li, Xue, et al.
Publicado: (2022)

Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis
por: Hu, Ping Ping, et al.
Publicado: (2022)

Editorial: Women in nanomedicine
por: Chuah, Lay-Hong, et al.
Publicado: (2023)

Editorial: Translating nanomedicines for anti-cancer treatment
por: Siram, Karthik, et al.
Publicado: (2023)

Editorial: Nanomedicine in Infectious Diseases: Drug Delivery and Vaccines
por: Marepally, Srujan, et al.
Publicado: (2022)

Functional Nanomedicines for Targeted Therapy of Bladder Cancer
por: Tang, Chao, et al.
Publicado: (2021)

Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective
por: Nakhlband, Ailar, et al.
Publicado: (2018)

Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells
por: He, Lili, et al.
Publicado: (2016)

Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy
por: Ding, Lei, et al.
Publicado: (2022)

Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
por: Chen, Wei, et al.
Publicado: (2021)

Advances in natural compound-based nanomedicine and the interaction with gut microbiota in ulcerative colitis therapy
por: Zhang, Jinlan, et al.
Publicado: (2023)

Editorial: New Advances in RNA Targeting
por: Ilinskaya, Olga, et al.
Publicado: (2020)

Editorial: Advanced Theranostic Nanomedicine in Oncology
por: Tapeinos, Christos, et al.
Publicado: (2020)

Activation of cancer immunotherapy by nanomedicine
por: Wang, Lijuan, et al.
Publicado: (2022)

Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
por: Zhang, Bo, et al.
Publicado: (2017)

Advances in immunotherapy modalities for atherosclerosis
por: Meng, Qingwen, et al.
Publicado: (2023)

Application Perspectives of Nanomedicine in Cancer Treatment
por: Hou, Shanshan, et al.
Publicado: (2022)

Ferroptosis-Inducing Nanomedicine for Cancer Therapy
por: Wang, Yang, et al.
Publicado: (2021)

Editorial: Nanomedicine in Cancer Targeting and Therapy
por: Longo, João Paulo Figueiró, et al.
Publicado: (2021)

Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis
por: Peters, Linsey J. F., et al.
Publicado: (2021)

Editorial commentary on the special issue of Advances in Nanomedicine
por: Reimhult, Erik, et al.
Publicado: (2021)

Nanotechnology for Targeted Therapy of Atherosclerosis
por: Hossaini Nasr, Seyedmehdi, et al.
Publicado: (2021)

The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies
por: Yang, Fan, et al.
Publicado: (2023)

Biomimetic nanomedicines for precise atherosclerosis theranostics
por: Tao, Ying, et al.
Publicado: (2023)

Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
por: Jiang, Yichuan, et al.
Publicado: (2023)

Pharmacologic therapies of ARDS: From natural herb to nanomedicine
por: Meng, Linlin, et al.
Publicado: (2022)

Editorial: Recent advances in novel therapeutic molecules and targets for inflammatory diseases
por: Li, Feng, et al.
Publicado: (2023)

Resveratrol on the Metabolic Reprogramming in Liver: Implications for Advanced Atherosclerosis
por: Ma, Ying, et al.
Publicado: (2021)

Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice
por: Morin, Emily E., et al.
Publicado: (2020)

Macrophage Death as a Pharmacological Target in Atherosclerosis
por: Martinet, Wim, et al.
Publicado: (2019)

The Potential of Chitosan in Nanomedicine: An Overview of the Cytotoxicity of Chitosan Based Nanoparticles
por: Frigaard, Julie, et al.
Publicado: (2022)

Editorial: Advances in Drug Formulation
por: Mukherjee, Biswajit, et al.
Publicado: (2020)

Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets
por: Blas-García, Ana, et al.
Publicado: (2022)

Editorial: Advance in translational research of preterm birth and related pregnancy
por: Xie, Han, et al.
Publicado: (2022)

Editorial: Drug Development and Target Discovery in Pulmonary Vascular Diseases
por: Zhang, Rui, et al.
Publicado: (2020)

Editorial: Therapeutic Advances in Melatonin Research
por: López-Muñoz, Francisco, et al.
Publicado: (2022)

New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
por: Luan, Yi, et al.
Publicado: (2022)

Editorial: Recent Advances in Cardiotoxicity Testing
por: Mohamed, Tamer M. A., et al.
Publicado: (2021)

Editorial: Advances in drug-induced diseases
por: Liu, Yao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jcjrrahd7i8rmenp1ser68cstk